A trial published in "ERJ Open Research" showed that in people with house dust mite (HDM)-driven asthma, Omalizumab in conjunction with allergen immunotherapy (AIT) was more efficacious in alleviating symptoms and lowering the daily dose of inhaled corticosteroids than AIT alone or Omalizumab alone. In patients with asthma brought on by HDM, researchers wanted to examine the efficacy of allergen immunotherapy when given with and without Omalizumab.

A total of 52 volunteers with HDM-driven asthma were recruited. Only patients who had monosensitization to HDM were included. The three treatment modalities—Omalizumab alone, HDM subcutaneous immunotherapy (SCIT) with Omalizumab, and SCIT alone—were contrasted in the research. The Asthma Control Questionnaire (ACQ) score, frequency of asthma exacerbations, and the decrease in the daily dose of inhaled steroids throughout the course of a 12-month observation period were the primary endpoints ascertained in this placebo-controlled, multicentre, three-armed, parallel-group, randomized trial.

After 12 months of treatment, all therapeutic modalities significantly reduced asthma exacerbations and improved ACQ scores in all variants of therapy. In the groups receiving Omalizumab alone (650±150 mcg versus 500±50 mcg) or HDM-SCIT+Omalizumab (550±250 mcg against 375±75 mcg), a clinically meaningful decrease in the daily dosages of inhaled corticosteroids was seen, favoring the latter group. Hence, the addition of a biologic to allergen immunotherapy boosts treatment effectiveness. The combination of Omalizumab and AIT seems to be a valuable approach to minimize adverse events and enhance the effectiveness of AIT itself.